Arrosy Leadri Surya, Novida Hermina
Department of Internal Medicine, Faculty of Medicine, Universitas Airlangga - Dr. Soetomo General Academic Hospital, Surabaya, Indonesia.
Ann Med Surg (Lond). 2022 Sep 15;82:104720. doi: 10.1016/j.amsu.2022.104720. eCollection 2022 Oct.
Congenital hypogonadotropic hypogonadism (CHH) is a rare disorder caused by insufficient gonadotropin-releasing hormone (GnRH) production.
An Indonesian adolescent, 22 years old, Javanese ethnic, complained of a small penis, low sexual desire, fatigue, and anosmia since childhood. Medical history stated that the patient had low testosterone levels 7 years ago and received testosterone once. Testosterone, luteinizing hormone (LH), and follicle-stimulating hormone (FSH) were decreased. The testicular ultrasound result was bilateral microtestis, suspicious of bilateral hypoplasia of the epididymis. Brain MRI also supports the diagnosis of hypogonadotropic hypogonadism, and the patient received Sustanon of 250 mg/2 weeks. The patient showed a good prognosis after 1 month of therapy.
The success of CHH therapy must be explored to improve its management.
CHH in an Indonesian male shows a good prognosis with testosterone injection.
先天性低促性腺激素性性腺功能减退（CHH）是一种由促性腺激素释放激素（GnRH）分泌不足引起的罕见疾病。
一名22岁的印度尼西亚青少年，爪哇族，自童年起就抱怨阴茎短小、性欲低下、疲劳和嗅觉丧失。病史显示患者7年前睾酮水平较低，曾接受过一次睾酮治疗。睾酮、黄体生成素（LH）和卵泡刺激素（FSH）均降低。睾丸超声结果为双侧小睾丸，怀疑双侧附睾发育不全。脑部MRI也支持低促性腺激素性性腺功能减退的诊断，患者接受了每2周250毫克的长效睾酮治疗。治疗1个月后患者预后良好。
必须探索CHH治疗的成功方法以改善其管理。
印度尼西亚男性CHH患者注射睾酮后预后良好。
